Whole mouth microbiota effects following subgingival delivery of sanguinarium.
An increased incidence of antibiotic-resistant bacteria and yeast overgrowth has been reported following various periodontal treatments. The objective of this study was to detect possible overgrowth of opportunistic bacteria and fungi as well as changes in normal microbiota after application of a biodegradable delivery system containing 5% sanguinarium (ABDS-S) to one quadrant in a split-mouth study. An oral hygiene quadrant served as a control. The ABDS-S treated and control periodontal sites as well as the saliva of 17 subjects were sampled prior to treatment, immediately after ABDS-S removal at 7 days, and again at 30 and 60 days. At Day 7 sanguinarium-resistant bacteria increased in both control and ABDS-S periodontal sites as well as in the saliva. Enteric Gram-negative bacilli in both control and ABDS-S periodontal sites were 2.2 to 3.4 log colony forming units higher at Day 7 compared to baseline. This overgrowth was transient in that levels became undetectable at Days 30 and 60. No such overgrowth was observed for C. albicans or other fungi, or for S. aureus or other staphylococci in any periodontal sites. Levels of Actinomyces increased at Days 30 and 60 in both control and ABDS-S sites as well as saliva. These changes strongly suggest that a 7 day ABDS-S treatment in one quadrant of the mouth led to significant microbiota changes in the treated and control quadrants as well as in the saliva. Future microbial studies involving antimicrobials delivered by local delivery systems must consider the crossover effects of treatment inherent in the split-mouth design.
Atrix Laboratories, Inc., Ft. Collins, CO, USA.
K C
KC
Godowski
E D
ED
Wolff
D M
DM
Thompson
C J
CJ
Housley
A M
AM
Polson
R L
RL
Dunn
S P
SP
Duke
N H
NH
Stoller
G L
GL
Southard
D000328:Adult; D000368:Aged; D000470:Alkaloids / Q000008:administration & dosage / Q000494:pharmacology*; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects*; D053119:Benzophenanthridines; D001673:Biodegradation, Environmental; D002176:Candida albicans / Q000187:drug effects; D018592:Cross-Over Studies; D016503:Drug Delivery Systems; D004352:Drug Resistance, Microbial; D004755:Enterobacteriaceae / Q000187:drug effects; D005260:Female; D005658:Fungi / Q000187:drug effects; D005881:Gingiva; D006801:Humans; D007546:Isoquinolines; D008297:Male; D008875:Middle Aged; D009055:Mouth / Q000382:microbiology*; D009910:Oral Hygiene; D010518:Periodontitis / Q000382:microbiology; D012463:Saliva / Q000382:microbiology; D016037:Single-Blind Method; D013210:Staphylococcus / Q000187:drug effects; D013211:Staphylococcus aureus / Q000187:drug effects; D013997:Time Factors
D000470:Alkaloids; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000935:Antifungal Agents; D053119:Benzophenanthridines; D007546:Isoquinolines; C005705:sanguinarine